Navigation Links
In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Date:9/25/2013

BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in Turkey will grow at an annual rate of four percent, reaching $90 million in 2017. The Emerging Markets report entitled Colorectal Cancer in Turkey finds that the rapidly growing CRC patient population, the launches of several new branded therapies, and the continued use of branded agents, in particular targeted therapies, Roche's Avastin (Altuzan in Turkey) and Merck's Erbitux, will drive growth in this market.

Between 2012 and 2017, five branded CRC therapies will launch in Turkey, namely Amgen's Vectibix (launched in Turkey in May 2013), Bayer's Stivarga, Sanofi's Zaltrap, Alchemia's HA-irinotecan and Eli Lilly's ramucirumab. As a result of current therapies being well entrenched in the market, new therapies will provide some competition to the existing agents but will not substantially diminish their patient shares—new therapies will together contribute 11 percent to the total CRC market in 2017.

The report also finds that the number of incident cases of CRC in Turkey will almost double between 2012 and 2022, mainly due to an increase in disease risk, but also because of growing and aging population.

"Turkish oncologists frequently use targeted therapies when treating their metastatic CRC patients and interviewed experts report that all of their metastatic patients undergo KRAS testing–this is more in line with the medical practice of the major markets than of some other emerging markets that we cover," said Decision Resources Analyst Natalia Reoutova, MA, MSc. "Although the drug price cuts implemented by the Turkish government have an obvious constraining effect on the market equally, they also allow the targeted agents to enjoy the comparatively high patient shares, which otherwise would be a lot lower."

The new report features extensive primary research with Turkish oncologists as well as a market outlook through 2017.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
2. New Drug that Delivers Targeted Radiation Minimizes Pain and May Extend Prostate Cancer Survival
3. MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
4. Protein Targeted For Cancer Drug Development Is Essential For Normal Heart Function
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
9. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
10. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
11. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):